XENETIC BIOSCIENCES, INC. Gain (Loss) on Repurchase of Debt Instrument
XENETIC BIOSCIENCES, INC. (XBIO) reported Gain (Loss) on Repurchase of Debt Instrument of -$1.69 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-31.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnRepurchaseOfDebtInstrument · last filed 2017-03-31
- XENETIC BIOSCIENCES, INC. gain (loss) on repurchase of debt instrument for fiscal 2016 was -$1.69M.
- XENETIC BIOSCIENCES, INC. gain (loss) on repurchase of debt instrument for fiscal 2015 was -$59.61K.
| Period end | Gain (Loss) on Repurchase of Debt Instrument 12 month |
|---|---|
| 2016-12-31 | -$1.69M 10-K · filed 2017-03-31 |
| 2015-12-31 | -$59.61K 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |